Literature DB >> 9890351

Arytenoid adduction as an adjunct to type I thyroplasty for unilateral vocal cord paralysis.

D H Kraus1, R F Orlikoff, S S Rizk, D B Rosenberg.   

Abstract

BACKGROUND: Surgical management of unilateral vocal cord paralysis has evolved over the last three decades. The recent use of type I thyroplasty has resulted in improvements in voice, swallowing, and respiration. The study was performed to evaluate our experience in 28 patients undergoing arytenoid adduction as part of their surgical rehabilitation of unilateral vocal cord paralysis.
METHODS: Patients undergoing arytenoid adduction with or without silastic medialization for unilateral vocal cord paralysis were entered into a prospective data base. Evaluation included symptomatic improvement in hoarseness, aspiration, dysphagia, dyspnea, and the radiographic documentation of pneumonia. Objective evaluation included mean phonatory air flow and acoustic analysis. Complications associated with surgery were recorded.
RESULTS: A satisfactory result was obtained in 27 of 28 (96%) patients. By symptom, improvement in hoarseness was evident in 96%, dyspnea 80%, dysphagia 94%, and aspiration 84%. Improvements in phonatory flow rate (p < .001), estimated mean laryngeal airway resistance (p < .001), and maximally prolonged phonation (p < .01) were identified. Complications occurred in 18% and consisted of local wound sepsis (n = 1), hematoma (n = 1), seroma (n = 1), and transient airway edema (n = 2). There were no episodes of airway obstruction requiring tracheostomy or implant extrusion.
CONCLUSIONS: Arytenoid adduction as part of type I thyroplasty is a safe and effective procedure. Subjective analysis confirms marked improvement in laryngeal function in the form of speech, swallowing, and respiration. Objective analysis confirms improvement in voice parameters. Future directions will focus on determination of those patients best served by arytenoid adduction.

Entities:  

Mesh:

Year:  1999        PMID: 9890351     DOI: 10.1002/(sici)1097-0347(199901)21:1<52::aid-hed7>3.0.co;2-h

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  8 in total

1.  Optimal arytenoid adduction based on quantitative real-time voice analysis.

Authors:  Matthew R Hoffman; Ketan Surender; William J Chapin; Rachel E Witt; Timothy M McCulloch; Jack J Jiang
Journal:  Laryngoscope       Date:  2011-01-13       Impact factor: 3.325

2.  Analysis of Dysphagia and Cough Strength in Patients with Unilateral Vocal Fold Paralysis.

Authors:  Kazutaka Kashima; Kenichi Watanabe; Takeshi Sato; Yukio Katori
Journal:  Dysphagia       Date:  2021-03-17       Impact factor: 3.438

3.  [Treatment of glottal gap].

Authors:  S Voigt-Zimmermann; C Arens
Journal:  HNO       Date:  2013-02       Impact factor: 1.284

Review 4.  Voice outcome indicators for unilateral vocal fold paralysis surgery: a review of the literature.

Authors:  G Desuter; M Dedry; B Schaar; J van Lith-Bijl; P P van Benthem; E V Sjögren
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-12-20       Impact factor: 2.503

5.  Framework Surgery for Treatment of Unilateral Vocal Fold Paralysis.

Authors:  James J Daniero; C Gaelyn Garrett; David O Francis
Journal:  Curr Otorhinolaryngol Rep       Date:  2014-06-01

6.  A comprehensive 6-year retrospective study on medialisation thyroplasty in the Indian population.

Authors:  Nupur Kapoor Nerurkar; Shweta Mahadev Pawar; Shalaka Nilesh Dighe
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-03-22       Impact factor: 2.503

7.  Revision laryngeal framework surgery performed by directly pulling the lateral cricoarytenoid muscle.

Authors:  T Kanazawa; D Komazawa; Y Watanabe; K Ichimura
Journal:  J Laryngol Otol       Date:  2014-08-14       Impact factor: 1.469

8.  Autologous thyroid cartilage graft implantation in medialization laryngoplasty: a modified approach for treating unilateral vocal fold paralysis.

Authors:  Ming-Shao Tsai; Ming-Yu Yang; Geng-He Chang; Yao-Te Tsai; Meng-Hung Lin; Cheng-Ming Hsu
Journal:  Sci Rep       Date:  2017-07-06       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.